This study evaluates the acute toxicity and feasibility of repeat breast conserving therapy with preoperative accelerated partial breast re-irradiation (PAPBI) in female patients aged 51 years or older with ipsilateral recurrent or second primary low-risk breast cancer or DCIS.
Female patients ≥ 51 years
Ipsilateral breast cancer; recurrence or second primary
Either histologically proven invasive adenocarcinoma (invasive adenocarcinoma with DCIS component is also accepted) or DCIS alone (calcification associated on imaging)
Histologically proven estrogen receptor positive
≥ grade 3 radiotherapy toxicity in the breast after treatment of the primary tumor
Previous boost radiotherapy is not allowed, UNLESS the protocol tumor lies outside of the original boost area
Distant metastases and/or synchronous contralateral invasive or in situ carcinoma
Invasive lobular carcinoma (ILC) or pleiomorphic lobular carcinoma in situ (LCIS)
The Netherlands Cancer Institute
Lead sponsor
Medical Center Haaglanden
Collaborator
Erasmus Medical Center
Collaborator